We empower people everywhere to live naturally healthier lives
Nature
We discover, unlock and clinically demonstrate the efficacy of the superpowers of nature hidden within peptides.
Consumer
To empower consumers to live healthier lives, naturally by making the products they consume everyday safer, healthier and greener.
Customer
To help our customers innovate at speed with unique and exclusive bioactive peptides.
Our Vision
At Nuritas, we make everyday products safer, healthier and greener!
Using our AI Magnifier technology platform and the transformative power of intelligent, patented peptides that are hidden in nature, we empower people everywhere to live naturally healthier lives.
Our Team
The beating heart of Nuritas is our incredibly passionate team
At Nuritas, our passionate team features a mix of different nationalities. We are very proud of our gender balance with 50% women and men across our team.
OUR SCIENTIFIC ACHIEVEMENTS
0
860 years of cumulative research experience
860 years of cumulative research experience
0
17 peer reviewed papers published
17 peer reviewed papers published
0
56 patents issued
56 patents issued
OUR HISTORY
Through years of research...
Nuritas has learnt to speak the language of life and translate nature into innovation.
Our People
Team
Close
Christopher Lindsay
Chief Commerical Officer
Chris has been in the biotech industry for nearly 30 years as an executive in both business and R&D leadership roles for start-ups as well as large multinational companies. Career highlights include twenty years with Martek Biosciences (Columbia, Maryland) where he built Martek’s nascent Dietary Supplement & Pharma ingredient division to a thriving global business, and seven years with DSM Nutritional Products (Kaiseraugst, Switzerland) where he helped lead DSM’s omega-3 business global expansion. In addition to Martek and DSM, Chris was an executive leader at several other successful technology B2B and B2C startups where he drove rapid revenue growth. Prior to his many years in business leadership, Chris started his career in R&D which will bring unique insights as we continue to translate Nuritas’ transformative innovation into commercial success. He holds an M.S. in Biotechnology from the Johns Hopkins University.
Chris has been in the biotech industry for nearly 30 years as an executive in both business and R&D leadership roles for start-ups as well as large multinational companies. Career highlights include twenty years with Martek Biosciences (Columbia, Maryland) where he built Martek’s nascent Dietary Supplement & Pharma ingredient division to a thriving global business, and seven years with DSM Nutritional Products (Kaiseraugst, Switzerland) where he helped lead DSM’s omega-3 business global expansion. In addition to Martek and DSM, Chris was an executive leader at several other successful technology B2B and B2C startups where he drove rapid revenue growth. Prior to his many years in business leadership, Chris started his career in R&D which will bring unique insights as we continue to translate Nuritas’ transformative innovation into commercial success. He holds an M.S. in Biotechnology from the Johns Hopkins University.
Close
Amanda D.H. Allen
Chief Financial Officer
Amanda joined Nuritas in 2024 as Chief Financial Officer, having spent the previous four years as CFO for a data technology company called LightBox. Prior to that, she was the CFO for High Ridge Brands and also held strategy and corporate finance roles at large multinationals such as PepsiCo and medium sized private equity backed companies such as Edible Arrangements and Waterworks. She began her career in investment banking.
She is an advisory board member for New York University’s Center for Sustainability. She graduated with honors from both Duke University with a bachelor of science degree in economics and New York University Stern School of Business with a masters of business administration.
Amanda joined Nuritas in 2024 as Chief Financial Officer, having spent the previous four years as CFO for a data technology company called LightBox. Prior to that, she was the CFO for High Ridge Brands and also held strategy and corporate finance roles at large multinationals such as PepsiCo and medium sized private equity backed companies such as Edible Arrangements and Waterworks. She began her career in investment banking.
She is an advisory board member for New York University’s Center for Sustainability. She graduated with honors from both Duke University with a bachelor of science degree in economics and New York University Stern School of Business with a masters of business administration.
Close
John Casey
Chief Manufacturing & Supply Chain Officer
John Casey, has over 30 years of experience in the food and healthcare industry with unique expertise in manufacturing and supply chain, John is a worldwide expert in protein hydrolysates. He began his career in Abbott Infant Nutritional’s, and since then he has worked in various supply chain and manufacturing roles with Wyeth Infant Nutritional’s (now Nestle Infant Nutritional’s) and GE Healthcare. Most recently, he held the position of Vice President of Operations and Supply Chain for Kerry Group’s Applied Health and Nutrition division. John will be overseeing the proprietary manufacturing process at Nuritas.
John Casey, has over 30 years of experience in the food and healthcare industry with unique expertise in manufacturing and supply chain, John is a worldwide expert in protein hydrolysates. He began his career in Abbott Infant Nutritional’s, and since then he has worked in various supply chain and manufacturing roles with Wyeth Infant Nutritional’s (now Nestle Infant Nutritional’s) and GE Healthcare. Most recently, he held the position of Vice President of Operations and Supply Chain for Kerry Group’s Applied Health and Nutrition division. John will be overseeing the proprietary manufacturing process at Nuritas.
Close
Dr. Andy Franklyn-Miller
Chief Medical and Innovation Officer
Dr. Franklyn-Miller, a highly accomplished physician and with expertise in physiology, clinical design, and science communication. He has a Ph.D. in Biomechanics and served in the Royal Navy and Royal Marines for 16 years. Dr. Franklyn-Miller has extensive experience in working with high-profile sports teams and elite performers and has published more than 60 peer-reviewed papers. He is an editor of the British Journal of Sports Medicine and has authored a textbook and an IOC Handbook. With his expertise in machine learning, clinical trials, and end user analysis, he will oversee several departments at Nuritas, including software engineering, data curation, data science, proteomics, lab, and regulatory departments.
Dr. Franklyn-Miller, a highly accomplished physician and with expertise in physiology, clinical design, and science communication. He has a Ph.D. in Biomechanics and served in the Royal Navy and Royal Marines for 16 years. Dr. Franklyn-Miller has extensive experience in working with high-profile sports teams and elite performers and has published more than 60 peer-reviewed papers. He is an editor of the British Journal of Sports Medicine and has authored a textbook and an IOC Handbook. With his expertise in machine learning, clinical trials, and end user analysis, he will oversee several departments at Nuritas, including software engineering, data curation, data science, proteomics, lab, and regulatory departments.
Close
Sean McGrath
Chief HR Officer
Sean McGrath is a highly seasoned global CHRO and Executive VP, with extraordinary execution skills and a career in global, growing organizations in the USA and Ireland.
Sean holds a BA from University College Galway, a master’s from Dublin City University, and a doctorate in Business Administration from Durham University in the UK. After starting his career in the Irish Defense Forces, he then went on to lead a range of senior HR positions in both manufacturing and financial services organizations, before moving back to Ireland and joining the Health Service Executive (HSE) as their HR in 2007. Over the next five years, he led an HR Function for the largest workforce in Ireland where he oversaw 10 different public sector trade unions, representing over 110,00 staff across the country.
Following his time at the HSE he spent six years as the Executive Vice President at the World Bank Group in Washington DC. In this position he led a significant change program that ensured the Bank was positioned for its next phase of growth. Prior to his appointment at Nuritas, McGrath acted as the Chief People Officer for ContourGlobal PLC, a power generation business listed on the London Stock Exchange.
Sean McGrath is a highly seasoned global CHRO and Executive VP, with extraordinary execution skills and a career in global, growing organizations in the USA and Ireland.
Sean holds a BA from University College Galway, a master’s from Dublin City University, and a doctorate in Business Administration from Durham University in the UK. After starting his career in the Irish Defense Forces, he then went on to lead a range of senior HR positions in both manufacturing and financial services organizations, before moving back to Ireland and joining the Health Service Executive (HSE) as their HR in 2007. Over the next five years, he led an HR Function for the largest workforce in Ireland where he oversaw 10 different public sector trade unions, representing over 110,00 staff across the country.
Following his time at the HSE he spent six years as the Executive Vice President at the World Bank Group in Washington DC. In this position he led a significant change program that ensured the Bank was positioned for its next phase of growth. Prior to his appointment at Nuritas, McGrath acted as the Chief People Officer for ContourGlobal PLC, a power generation business listed on the London Stock Exchange.
Close
Dr Nora Khaldi
FOUNDER AND CEO
Nora is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.
Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.
Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.
Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This ground-breaking find put into question many of the phylogenetic methods currently in use today.
Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.
Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.
Nora is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.
Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.
Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.
Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This ground-breaking find put into question many of the phylogenetic methods currently in use today.
Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.
Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.
Board
Close
Dr. Alan Barton
Alan is a distinguished professional who possesses a combination of scientific expertise and business acumen. He obtained a Master’s degree in Chemistry from Oxford University and a Ph.D. in Organic Chemistry from Harvard, which provided him with an in-depth understanding of the field. Currently based in the USA, Alan has established a remarkable career in the specialty materials industry, where he has excelled in both the corporate and venture worlds. He has a proven track record of successfully growing the revenue and valuation of companies he has worked for, and his expertise in taking new technologies to market has been instrumental in his achievements. Alan has a profound understanding of the scientific and commercial aspects of products and the processes involved in their commercialization.
Alan is a distinguished professional who possesses a combination of scientific expertise and business acumen. He obtained a Master’s degree in Chemistry from Oxford University and a Ph.D. in Organic Chemistry from Harvard, which provided him with an in-depth understanding of the field. Currently based in the USA, Alan has established a remarkable career in the specialty materials industry, where he has excelled in both the corporate and venture worlds. He has a proven track record of successfully growing the revenue and valuation of companies he has worked for, and his expertise in taking new technologies to market has been instrumental in his achievements. Alan has a profound understanding of the scientific and commercial aspects of products and the processes involved in their commercialization.
Close
Randall Lewis
Randall has assisted companies in accessing capital as founder of Exodus Commercial Capital and has served as its President since 2013. He has over 30 years of finance and operations experience that includes Fortune 50 companies such as GE Capital, Wells Fargo and Anthem. Randall has held various executive leadership roles, including: Executive Vice President and Chief Compliance Officer, Executive Vice President and Chief Auditor and Managing Director of Corporate Development. His experience includes the closing of several mergers and acquisitions for over $2B. He also served as CEO for a start-up logistics firm, s2f worldwide, LLC; that was sold to a Fortune 500 company.
He obtained his Bachelor of Science degree in General Management/Accounting and MBA in Finance from Purdue University.
Randall has assisted companies in accessing capital as founder of Exodus Commercial Capital and has served as its President since 2013. He has over 30 years of finance and operations experience that includes Fortune 50 companies such as GE Capital, Wells Fargo and Anthem. Randall has held various executive leadership roles, including: Executive Vice President and Chief Compliance Officer, Executive Vice President and Chief Auditor and Managing Director of Corporate Development. His experience includes the closing of several mergers and acquisitions for over $2B. He also served as CEO for a start-up logistics firm, s2f worldwide, LLC; that was sold to a Fortune 500 company.
He obtained his Bachelor of Science degree in General Management/Accounting and MBA in Finance from Purdue University.
Close
Stephan Dolezalek
Stephan joined the Grosvenor Food & AgTech (formerly known as Wheatsheaf Group) Board as a Non-Executive Director in May 2017. Since then, he has assumed increasing responsibilities within the Group, becoming a full time Executive Director in January 2019.
Stephan has worked with entrepreneurial growth companies since the 1980s. He has been a private equity investor since 1999, investing in software, communications technology, biotechnology, clean energy and agricultural businesses. He led VantagePoint Capital Partners’ $1Bn CleanTech Fund from its inception. More recently he served as a senior advisor in forming the Breakthrough Energy Ventures fund and was the Managing Partner of Resourcient Group LLC. Stephan has also acted as co-founder of several companies and has helped “raise” five “unicorn” companies reaching valuations of between $1 and $100bn.
Stephan is a graduate of the School of Architecture at the University of Virginia (BCP) and the University of Virginia School of Law (JD).
Stephan joined the Grosvenor Food & AgTech (formerly known as Wheatsheaf Group) Board as a Non-Executive Director in May 2017. Since then, he has assumed increasing responsibilities within the Group, becoming a full time Executive Director in January 2019.
Stephan has worked with entrepreneurial growth companies since the 1980s. He has been a private equity investor since 1999, investing in software, communications technology, biotechnology, clean energy and agricultural businesses. He led VantagePoint Capital Partners’ $1Bn CleanTech Fund from its inception. More recently he served as a senior advisor in forming the Breakthrough Energy Ventures fund and was the Managing Partner of Resourcient Group LLC. Stephan has also acted as co-founder of several companies and has helped “raise” five “unicorn” companies reaching valuations of between $1 and $100bn.
Stephan is a graduate of the School of Architecture at the University of Virginia (BCP) and the University of Virginia School of Law (JD).
Close
Nick Rosa
Nick Rosa is co-founder and Managing Director of Sandbox Industries and Managing Director of Cultivian Sandbox. Nick serves as a Director or advisor to several companies, such as the Blue Cross Blue Shield Venture Fund, Healthbox Global Partners, Oncology Analytics, Nuritas, TechStars Chicago and The Chicago Innovation Awards.
Prior to forming Sandbox, Nick led the buyout and served as CEO of The NutraSweet Company. As a senior executive at Monsanto, he led the Nutrition and Consumer Products division, overseeing NutraSweet, the consumer Lawn and Garden Business, and Kelco food ingredients business. Nick also served as a Senior Vice President and Advisor to the Board of Directors at Monsanto.
Previously, Nick held senior executive positions at Searle and has experience with Masonite Corporation and Baxter. He has lived and worked in several countries, including Kuwait, Switzerland and France. Nick has also been involved with numerous civic and commercial organizations. Nick holds a B.S. in Political Science from Northern Illinois University and an MBA from DePaul University.
Nick Rosa is co-founder and Managing Director of Sandbox Industries and Managing Director of Cultivian Sandbox. Nick serves as a Director or advisor to several companies, such as the Blue Cross Blue Shield Venture Fund, Healthbox Global Partners, Oncology Analytics, Nuritas, TechStars Chicago and The Chicago Innovation Awards.
Prior to forming Sandbox, Nick led the buyout and served as CEO of The NutraSweet Company. As a senior executive at Monsanto, he led the Nutrition and Consumer Products division, overseeing NutraSweet, the consumer Lawn and Garden Business, and Kelco food ingredients business. Nick also served as a Senior Vice President and Advisor to the Board of Directors at Monsanto.
Previously, Nick held senior executive positions at Searle and has experience with Masonite Corporation and Baxter. He has lived and worked in several countries, including Kuwait, Switzerland and France. Nick has also been involved with numerous civic and commercial organizations. Nick holds a B.S. in Political Science from Northern Illinois University and an MBA from DePaul University.
Close
Matthieu Vermesch
Matthieu has over 25 years of experience in investment management with a focus on Asian regions. Matthieu’s investment experience has been centred primarily on thematic investing where he has successfully identified specific themes and designed strategies to profit from them. In mid-2012, Matthieu started to explore the imbalance created by China in the world market of animal protein. He quickly became convinced that it was the tipping point of a multi-decade investment opportunity. In late 2013-early 2014, Matthieu decided to concentrate solely on this and founded New Protein Capital (NPC). The scope of investment of NPC has since been expanded to include the multiple challenges of the food and feed production processes.
Prior to founding NPC in 2014, Matthieu was with Everest Capital, a large independent investment firm with offices in the US and in Singapore, for over 16 years. At Everest Capital, he was a Senior Managing Director and the Director of Research as well as a member of the Executive and Investment committees. Prior to Everest, Matthieu was with Banque Paribas, in Hong Kong, New York, Taipei and Paris.
Matthieu has a postgraduate degree in Corporate Finance from Université Paris Dauphine and has a graduate degree from Institut d’Etudes Politiques de Paris (Sciences Po).
Matthieu has over 25 years of experience in investment management with a focus on Asian regions. Matthieu’s investment experience has been centred primarily on thematic investing where he has successfully identified specific themes and designed strategies to profit from them. In mid-2012, Matthieu started to explore the imbalance created by China in the world market of animal protein. He quickly became convinced that it was the tipping point of a multi-decade investment opportunity. In late 2013-early 2014, Matthieu decided to concentrate solely on this and founded New Protein Capital (NPC). The scope of investment of NPC has since been expanded to include the multiple challenges of the food and feed production processes.
Prior to founding NPC in 2014, Matthieu was with Everest Capital, a large independent investment firm with offices in the US and in Singapore, for over 16 years. At Everest Capital, he was a Senior Managing Director and the Director of Research as well as a member of the Executive and Investment committees. Prior to Everest, Matthieu was with Banque Paribas, in Hong Kong, New York, Taipei and Paris.
Matthieu has a postgraduate degree in Corporate Finance from Université Paris Dauphine and has a graduate degree from Institut d’Etudes Politiques de Paris (Sciences Po).
Close
Dr Nora Khaldi
FOUNDER AND CEO
Nora is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.
Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.
Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.
Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This ground-breaking find put into question many of the phylogenetic methods currently in use today.
Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.
Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.
Nora is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.
Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.
Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.
Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This ground-breaking find put into question many of the phylogenetic methods currently in use today.
Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.
Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.
Close
Dr Marie Asano
Marie Asano is currently a Partner at the European Circular Bioeconomy Fund, a specialized fund investing in growth-stage companies active in ag-tech, nutrition, industrial biotech and packaging. At ECBF Marie is the Partner leading the nutrition and food tech vertical. Previously she was at High-Tech Gründerfonds (HTGF), a German-based seed fund where she lead early stage investments active in the areas of chemistry, climate tech, animal health and life sciences. Before beginning her professional career, Marie completed her PhD in Chemistry at the universities of Liège and Bordeaux after which she then obtained an MBA at the Collège des Ingénieurs.
Marie Asano is currently a Partner at the European Circular Bioeconomy Fund, a specialized fund investing in growth-stage companies active in ag-tech, nutrition, industrial biotech and packaging. At ECBF Marie is the Partner leading the nutrition and food tech vertical. Previously she was at High-Tech Gründerfonds (HTGF), a German-based seed fund where she lead early stage investments active in the areas of chemistry, climate tech, animal health and life sciences. Before beginning her professional career, Marie completed her PhD in Chemistry at the universities of Liège and Bordeaux after which she then obtained an MBA at the Collège des Ingénieurs.
Advisory board
Close
Joerg Ohle
Joerg is a career veteran of the consumer and animal health arena having spent over 40 years at Bayer. During his tenure with Consumer Health he held positions as commercial head where he oversaw all sales and marketing activities in the EU, Asia-Pacific, as well as Latin America, and was responsible for over €3 billion in annual revenues as well as the acquisition of a plant-based OTC company. Joerg was an executive board member of the consumer health division and lead the go-to-market council on worldwide activities.
Joerg is a career veteran of the consumer and animal health arena having spent over 40 years at Bayer. During his tenure with Consumer Health he held positions as commercial head where he oversaw all sales and marketing activities in the EU, Asia-Pacific, as well as Latin America, and was responsible for over €3 billion in annual revenues as well as the acquisition of a plant-based OTC company. Joerg was an executive board member of the consumer health division and lead the go-to-market council on worldwide activities.
Close
Dr Will Li
William W. Li, MD, is a world-renowned physician, scientist, speaker, and author of ‘Eat To Beat Disease – The New Science of How Your Body Can Heal Itself’. He is best known for leading the Angiogenesis Foundation. His ground-breaking work has impacted more than 70 diseases including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, “Can We Eat to Starve Cancer?” has garnered more than 11 million views, and he has appeared on: Good Morning America, CNN, MSNBC, NPR, Voice of America; and in The Atlantic, TIME, and The New York Times. An author of over 100 scientific publications in leading journals such as Science, the New England Journal of Medicine, and The Lancet, Dr. Li has served on the faculties of Harvard Medical School, Tufts University, and Dartmouth Medical School.
William W. Li, MD, is a world-renowned physician, scientist, speaker, and author of ‘Eat To Beat Disease – The New Science of How Your Body Can Heal Itself’. He is best known for leading the Angiogenesis Foundation. His ground-breaking work has impacted more than 70 diseases including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, “Can We Eat to Starve Cancer?” has garnered more than 11 million views, and he has appeared on: Good Morning America, CNN, MSNBC, NPR, Voice of America; and in The Atlantic, TIME, and The New York Times. An author of over 100 scientific publications in leading journals such as Science, the New England Journal of Medicine, and The Lancet, Dr. Li has served on the faculties of Harvard Medical School, Tufts University, and Dartmouth Medical School.
Close
Indra Nooyi
Currently a Board Member at Amazon, Mrs. Nooyi was the former Chief Executive Officer of PepsiCo, Inc., from October 2006 to October 2018, where she also served as the Chairman of its board of directors from May 2007 to February 2019. Having joined PepsiCo. in 1994, she held numerous positions including Chief Financial Officer as well as roles in corporate strategy and development and strategic planning. She has been regularly listed among the World’s 100 most influential women.
Currently a Board Member at Amazon, Mrs. Nooyi was the former Chief Executive Officer of PepsiCo, Inc., from October 2006 to October 2018, where she also served as the Chairman of its board of directors from May 2007 to February 2019. Having joined PepsiCo. in 1994, she held numerous positions including Chief Financial Officer as well as roles in corporate strategy and development and strategic planning. She has been regularly listed among the World’s 100 most influential women.
Close
Prof J Bruce German
Throughout his illustrious, 40-year research career, Prof. German’s pivotal research has focused on improving foods and their ability to positively impact on health, using milk as the genetic blueprint for how foods can support health. During his career, he has been named to the Most Highly Cited Scientists List by ISI Index and has received honours including the President’s Award Canadian Federation of Biological Societies, John E Kinsella endowed chair University of California and Mention D’Honneur Du Jury ACADEMI MORIM.
Throughout his illustrious, 40-year research career, Prof. German’s pivotal research has focused on improving foods and their ability to positively impact on health, using milk as the genetic blueprint for how foods can support health. During his career, he has been named to the Most Highly Cited Scientists List by ISI Index and has received honours including the President’s Award Canadian Federation of Biological Societies, John E Kinsella endowed chair University of California and Mention D’Honneur Du Jury ACADEMI MORIM.